Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma

This article belongs to the Special Issue Advances in Multiple Myeloma Research and Treatment.

Detalles Bibliográficos
Autores: Puig, Noemi, Flores-Montero, Juan, Burgos, Leire, Cedena, Maria-Teresa, Cordón, Lourdes, Pérez, José J., Sanoja-Flores, Luzalba, Manrique, Irene, Rodríguez-Otero, Paula, Rosiñol, Laura, Martínez-López, Joaquín, Mateos, Maria Victoria, Lahuerta, Juan José, Bladé, Joan, San Miguel, Jesús F., Orfao, Alberto, Paiva, Bruno
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/262057
Acceso en línea:http://hdl.handle.net/10261/262057
Access Level:acceso abierto
Palabra clave:Multiple myeloma
Minimal residual disease
Hemodilution
id ES_2ad7ed7c62fbc45dedcef2e104f19cc2
oai_identifier_str oai:digital.csic.es:10261/262057
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
title Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
spellingShingle Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
Puig, Noemi
Multiple myeloma
Minimal residual disease
Hemodilution
title_short Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
title_full Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
title_fullStr Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
title_full_unstemmed Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
title_sort Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
dc.creator.none.fl_str_mv Puig, Noemi
Flores-Montero, Juan
Burgos, Leire
Cedena, Maria-Teresa
Cordón, Lourdes
Pérez, José J.
Sanoja-Flores, Luzalba
Manrique, Irene
Rodríguez-Otero, Paula
Rosiñol, Laura
Martínez-López, Joaquín
Mateos, Maria Victoria
Lahuerta, Juan José
Bladé, Joan
San Miguel, Jesús F.
Orfao, Alberto
Paiva, Bruno
author Puig, Noemi
author_facet Puig, Noemi
Flores-Montero, Juan
Burgos, Leire
Cedena, Maria-Teresa
Cordón, Lourdes
Pérez, José J.
Sanoja-Flores, Luzalba
Manrique, Irene
Rodríguez-Otero, Paula
Rosiñol, Laura
Martínez-López, Joaquín
Mateos, Maria Victoria
Lahuerta, Juan José
Bladé, Joan
San Miguel, Jesús F.
Orfao, Alberto
Paiva, Bruno
author_role author
author2 Flores-Montero, Juan
Burgos, Leire
Cedena, Maria-Teresa
Cordón, Lourdes
Pérez, José J.
Sanoja-Flores, Luzalba
Manrique, Irene
Rodríguez-Otero, Paula
Rosiñol, Laura
Martínez-López, Joaquín
Mateos, Maria Victoria
Lahuerta, Juan José
Bladé, Joan
San Miguel, Jesús F.
Orfao, Alberto
Paiva, Bruno
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Centro de Investigación Biomédica en Red Cáncer (España)
Instituto de Salud Carlos III
European Commission
Cancer Research UK
Fundación Científica Asociación Española Contra el Cáncer
Associazione Italiana per la Ricerca sul Cancro
International Myeloma Foundation
European Research Council
Paula and Rodger Riney Foundation
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Multiple myeloma
Minimal residual disease
Hemodilution
topic Multiple myeloma
Minimal residual disease
Hemodilution
description This article belongs to the Special Issue Advances in Multiple Myeloma Research and Treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/262057
url http://hdl.handle.net/10261/262057
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/EC/H2020/680200
http://dx.doi.org/10.3390/cancers13194924

dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405097993175040
spelling Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in MyelomaPuig, NoemiFlores-Montero, JuanBurgos, LeireCedena, Maria-TeresaCordón, LourdesPérez, José J.Sanoja-Flores, LuzalbaManrique, IreneRodríguez-Otero, PaulaRosiñol, LauraMartínez-López, JoaquínMateos, Maria VictoriaLahuerta, Juan JoséBladé, JoanSan Miguel, Jesús F.Orfao, AlbertoPaiva, BrunoMultiple myelomaMinimal residual diseaseHemodilutionThis article belongs to the Special Issue Advances in Multiple Myeloma Research and Treatment.[Simple Summary] Although the majority of patients with myeloma who achieve undetectable minimal residual disease show prolonged survival, some of them relapse shortly afterwards. False-negative results due to hemodiluted bone marrow samples could explain this inconsistency, but there is no guidance on how to evaluate them. We analyzed three cell populations normally absent in peripheral blood in 1404 aspirates obtained in numerous disease settings and in 85 healthy adults. Pairwise comparisons according to age and treatment showed significant variability, thus suggesting that hemodilution should be preferably evaluated with references obtained after receiving identical regimens. Leveraging the minimal residual disease results from 118 patients, we showed that a comparison with age-matched healthy adults could also inform on potential hemodilution. Our study supports the routine assessment of bone marrow cellularity to evaluate hemodilution, using as reference values either treatment-specific or from healthy adults if the former are unavailable.[Abstract] Background: Whereas, in most patients with multiple myeloma (MM), achieving undetectable MRD anticipates a favorable outcome, some others relapse shortly afterwards. Although one obvious explanation for this inconsistency is the use of nonrepresentative marrow samples due to hemodilution, there is no guidance on how to evaluate this issue. Methods: Since B-cell precursors, mast cells and nucleated red blood cells are normally absent in peripheral blood, we analyzed them in 1404 bone marrow (BM) aspirates obtained in numerous disease settings and in 85 healthy adults (HA). Results: First, we confirmed the systematic detection of the three populations in HA, as well as the nonreduced numbers with aging. Pairwise comparisons between HA and MM patients grouped according to age and treatment showed significant variability, suggesting that hemodilution should be preferably evaluated with references obtained from patients treated with identical regimens. Leveraging the MRD results from 118 patients, we showed that a comparison with HA of similar age could also inform on potential hemodilution. Conclusions: Our study supports the routine assessment of BM cellularity to evaluate hemodilution, since reduced BM-specific cell types as compared to reference values (either treatment-specific or from HA if the former are unavailable) could indicate hemodilution and a false-negative MRD result.This study was supported by grants from the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00400, CB16/12/00233 and CB16/12/00284); Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria and co-financed by FEDER funds (FIS No. PI15/01956, PI15/02049, PI15/02062, PI18/01709, PI18/01673 and PI19/01451); the Cancer Research UK (C355/A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR); the Black Swan Research Initiative of the International Myeloma Foundation and the European Research Council (ERC) 2015 Starting Grant (Contract 680200 MYELOMANEXT). This study was supported by the Riney Family Multiple Myeloma Research Program Fund.Multidisciplinary Digital Publishing InstituteCentro de Investigación Biomédica en Red Cáncer (España)Instituto de Salud Carlos IIIEuropean CommissionCancer Research UKFundación Científica Asociación Española Contra el CáncerAssociazione Italiana per la Ricerca sul CancroInternational Myeloma FoundationEuropean Research CouncilPaula and Rodger Riney FoundationConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2022202220212022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/262057reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/EC/H2020/680200http://dx.doi.org/10.3390/cancers13194924Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2620572026-05-22T06:33:51Z
score 15,811543